|
CN103130791A
|
|
Novel benzamides compound
|
|
CN103130792A
|
|
2-aminothiazoles compound
|
|
CN103070871A
|
|
Pharmaceutical composition of fulvestrant
|
|
CN102807568A
|
|
Thiadiazole derivative DPP-IV (dipeptidyl peptidase IV) inhibitor
|
|
CN102764260A
|
|
Pharmaceutical composition of camptothecin derivative and preparation method thereof
|
|
CN102757421A
|
|
Purification method of esomeprazole
|
|
CN102617612A
|
|
Biapenem B-type crystallinity
|
|
CN102617395A
|
|
Preparation method of glycylcycline antibiotic
|
|
CN102617611A
|
|
Preparation method of biapenem aseptic powder
|
|
CN102558150A
|
|
Synthesis process for sulfoxide substituted compound
|
|
CN102525880A
|
|
Aprepitant solid dispersion composition
|
|
WO2011103762A1
|
|
Lamivudine oxalate and preparation method thereof
|
|
CN102464640A
|
|
Preparation method of zanamivir
|
|
CN102344438A
|
|
Crystals of quinoline derivative and preparation methods thereof
|
|
CN102342921A
|
|
Pharmaceutical composition of prasugrel hydrobromide acetate compound
|
|
CN102106856A
|
|
Entecavir medicinal composition and preparation method thereof
|
|
CN102100677A
|
|
Entecavir dispersible tablets and preparation method thereof
|
|
TW201141877A
|
|
Synthesis method of glycyrrhetinic acid ester derivatives and deoxyglycyrrhetinic acid ester compounds
|
|
CN102138925A
|
|
Tigecycline composition and preparation method thereof
|
|
CN101991629A
|
|
Glaucescent fissistigma root saponin composition and preparation method thereof
|
